in the absence of a submission from the holder of the marketing authorisation
zilucoplan (Zilbrysq®) is not recommended for use within NHSScotland.
Indication under review: as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.
Download detailed advice261KB (PDF)
Medicine details
- Medicine name:
- zilucoplan (Zilbrysq)
- SMC ID:
- SMC2717
- Indication:
As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 September 2024